Want to see HYEX full AI Analyst Report?
Top Page
Healthy Extracts
(OTC:HYEX)
Select Model
Select Model
Rating:48Neutral
Price Target:
$0.89
▼(-23.85% Downside)
Action:Reiterated
Date:09/11/26
The score is primarily held back by weak technicals (price below all major moving averages and negative MACD) and continued net losses/negative operating profitability despite improving revenue and a shift to positive free cash flow. Added downside risk comes from multiple leadership resignations with vacancies left unfilled, while valuation support is limited due to a negative P/E.
Positive Factors
Revenue and Gross Margin
Revenue growth and a strong gross margin indicate improving scale and attractive underlying unit economics. If the company maintains this top-line expansion while controlling expenses, the broad gross-profit base could support eventual operating leverage and a more durable path toward profitability.
Negative Factors
Persistent Operating Losses
The company has not yet converted revenue growth and roughly 61% gross margins into sustainable operating profitability. Continued EBIT and net losses can consume financial resources, limit reinvestment capacity, and leave results vulnerable if growth slows or operating costs rise.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Gross Margin
Revenue growth and a strong gross margin indicate improving scale and attractive underlying unit economics. If the company maintains this top-line expansion while controlling expenses, the broad gross-profit base could support eventual operating leverage and a more durable path toward profitability.
Read all positive factors
Healthy Extracts (HYEX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.71M
Dividend YieldN/A
Average Volume (3M)347.00
Price to Earnings (P/E)―
Beta (1Y)2.37
Revenue Growth84.13%
EPS Growth38.29%
CountryUS
Employees22
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.16
Shares Outstanding14,741,348
10 Day Avg. Volume897
30 Day Avg. Volume347
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)0.59
Price to Sales (P/S)3.13
P/FCF Ratio96.73
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.13
Revenue Forecast (FY)$14.12M
Healthy Extracts Business Overview & Revenue Model
Company Description
Healthy Extracts Inc., through its various divisions, specializes in the global and domestic research, development, and sale of natural botanical products. Its portfolio encompasses dietary supplements crafted for cardiovascular wellness, alongsid...
Healthy Extracts Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
58
Neutral
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.29M | 4.51M | 3.11M | 2.49M | 2.25M | 1.47M |
| Gross Profit | 3.85M | 2.42M | 1.91M | 1.62M | 1.37M | 695.08K |
| EBITDA | -486.38K | -791.66K | -183.15K | -2.24M | -910.71K | -1.88M |
| Net Income | -879.36K | -881.12K | -840.67K | -2.47M | -983.12K | -1.99M |
Balance Sheet | ||||||
| Total Assets | 32.61M | 27.82M | 2.38M | 2.64M | 2.78M | 3.03M |
| Cash, Cash Equivalents and Short-Term Investments | 189.96K | 146.94K | 112.02K | 19.44K | 65.65K | 222.10K |
| Total Debt | 9.07M | 2.64M | 941.90K | 1.13M | 593.52K | 342.62K |
| Total Liabilities | 10.17M | 3.80M | 1.97M | 1.68M | 902.79K | 558.84K |
| Stockholders Equity | 22.44M | 24.03M | 410.38K | 954.59K | 1.88M | 2.47M |
Cash Flow | ||||||
| Free Cash Flow | 500.27K | 146.22K | 281.97K | -415.75K | -342.95K | -997.30K |
| Operating Cash Flow | 500.27K | 165.52K | 281.97K | -415.75K | -334.96K | -901.30K |
| Investing Cash Flow | 171.57K | 56.30K | 0.00 | 0.00 | -5.34K | -96.00K |
| Financing Cash Flow | -682.38K | -186.91K | -189.39K | 369.54K | 239.52K | 1.16M |
Healthy Extracts Technical Analysis
Negative
1.17
Price Trends
1.30
Negative
1.58
Negative
1.79
Negative
Market Momentum
-0.10
Positive
30.17
Neutral
15.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYEX, the sentiment is Negative. The current price of 1.17 is below the 20-day moving average (MA) of 1.21, below the 50-day MA of 1.30, and below the 200-day MA of 1.79, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 30.17 is Neutral, neither overbought nor oversold. The STOCH value of 15.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HYEX.
Healthy Extracts Risk Analysis
Healthy Extracts disclosed 11 risk factors in its most recent earnings report. Healthy Extracts reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
An active trading market for our Common Stock may not develop and you may not be able to resell your shares at or above the public offering price. Q4, 2023
2.
We have broad discretion in the use of our cash, and may not use it effectively. Q4, 2023
Healthy Extracts Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $32.08M | -5.73 | -14.03% | ― | -21.12% | -109.07% | |
52 Neutral | $95.74M | -8.94 | -47.10% | 21.69% | -25.68% | -244.92% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $25.52M | -0.38 | -118.89% | ― | 33.82% | 34.05% | |
48 Neutral | $13.71M | -5.66 | -3.72% | ― | 84.13% | 38.29% | |
46 Neutral | $48.16M | -2.63 | -21.10% | ― | 489.78% | 45.39% | |
37 Underperform | $21.36M | -0.46 | -148.91% | ― | -18.24% | -2264.65% |
* Healthcare Sector Average
HYEX
Healthy Extracts
0.93
-1.32
-58.67%
RMTI
Rockwell Med
7.96
-8.64
-52.05%
SCYX
SCYNEXIS
4.84
-3.96
-45.00%
AYTU
Aytu BioScience
1.99
-0.34
-14.59%
CPIX
Cumberland Pharmaceuticals
6.39
3.77
143.80%
COSM
Cosmos Holdings
0.25
-0.65
-71.89%
Healthy Extracts Corporate Events
Private Placements and Financing
Healthy Extracts Issues Convertible Promissory Note to Labrys
Neutral
Jul 24, 2026
On July 17, 2026, Healthy Extracts entered into a Securities Purchase Agreement under which it issued a $258,750 promissory note to LABRYS FUND II, L.P. The note carries a 10% annual interest rate earned upfront, includes a $33,750 original issue ...
Business Operations and StrategyExecutive/Board Changes
Healthy Extracts Faces Transition After Brand Officer Resigns
Negative
Jul 13, 2026
Healthy Extracts, a company operating in the health and wellness sector, focuses on developing and marketing branded products aimed at consumer wellbeing. Its brand strategy has been overseen by a chief brand officer responsible for guiding market...
Business Operations and StrategyExecutive/Board Changes
Healthy Extracts Announces Key Leadership Resignation and Transition
Negative
Jul 6, 2026
Healthy Extracts, operating in the health and wellness sector, focuses on products aimed at improving consumer well-being and performance. The company markets its offerings to customers seeking lifestyle and nutritional support, positioning itself...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.